N-benzyl tryptanthrin derivatives inhibit TDO and IDO1 enzymes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective TDO inhibitors to treat severe diseases related to abnormal expression or activation of TDO, such as liver cancer, glioma, and mental disorders, as current studies have shown TDO's significant role in tumor regulation and immune evasion, with limited research on TDO inhibitors in oncology.
Innovation Solution
The use of N-benzyl tryptanthrin derivatives as a pharmaceutical composition to inhibit TDO activity, which also exhibits dual inhibitory activity against IDO1 and TDO, potentially blocking the tryptophan metabolism kynurenine pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TDO inhibitors are developed to treat severe diseases related to abnormal TDO expression, then therapeutic effectiveness is improved, but research and development resources are limited due to lack of focus in this area
Solution Approach 1:
The N-benzyl tryptanthrin derivative is designed to inhibit multiple enzymes (TDO and IDO1) simultaneously, making a single compound applicable to multiple disease contexts where either enzyme is pathogenic. This multi-functionality allows the compound to address both TDO-specific diseases and diseases involving both TDO and IDO1, maximizing therapeutic versatility from a single molecular structure
2Measurement precision
If N-benzyl tryptanthrin derivative is used to inhibit TDO activity, then TDO inhibition efficacy is enhanced, but selectivity between TDO and IDO1 must be maintained
Solution Approach 1:
The molecular structure of the N-benzyl tryptanthrin derivative incorporates specific substituent patterns (R1, R2, R3, R4 groups) that create localized interaction zones within the enzyme binding pocket. These localized structural features enable the compound to distinguish between TDO and IDO1 active sites, achieving high TDO inhibition while maintaining appropriate selectivity and minimizing off-target effects
3Adaptability or versatility
If dual inhibitory activity against IDO1 and TDO is achieved, then broad-spectrum therapeutic potential is improved, but compound complexity increases
Solution Approach 1:
The patent merges the inhibitory functions for both TDO and IDO1 into a single molecular framework (the tryptanthrin core with N-benzyl substitution). By combining multiple inhibitory activities into one compound rather than using separate agents, the patent achieves broad therapeutic scope while managing complexity through unified molecular design rather than multiple separate interventions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The N-benzyl tryptanthrin derivative effectively inhibits TDO and IDO1, providing a novel approach for treating TDO-related diseases and tryptophan metabolic disorders, with enhanced inhibitory effects on TDO compared to existing compounds.
Implementation Method 1
The N-benzyl tryptanthrin derivative effectively inhibits TDO and IDO1, providing a novel approach for treating TDO-related diseases and tryptophan metabolic disorders
Data Source
AI summary
The present invention provides an application of N-benzyl tryptanthrin derivative as tryptophan dioxygenase (TDO) inhibitor, and more specifically an application of N-benzyl tryptanthrin derivative or a pharmaceutically acceptable salt thereof. Said derivative has a structural general formula as represented by formula 1, wherein each group is defined as in the specification. The derivative of the present invention has a good TDO inhibiting activity and can be used to prepare a treatment for diseases associated with TDO activity and expression.